W. L. Gore & Associates (Gore) announced at the annual International Congress of Endovascular Interventions XXII, that it has received approval from the US Food & Drug Administration (FDA) to market a modified version of the GORE TAG Thoracic Endoprosthesis for the treatment of thoracic aortic aneurysms (TAAs). The improved delivery catheter enhances the previous version of the GORE TAG Thoracic Endoprosthesis by adding a soft flexible tip to the leading end of the delivery system. The soft tip improves flexibility at the wire / catheter interface to facilitate tracking through challenging aortic anatomy. The hub component has also been modified to improve ease of use and durability.

In North America, the GORE TAG Thoracic Endoprosthesis is the leading option for less invasive treatment of TAA, an aneurysm of the descending thoracic aorta, the body's main circulatory vessel. TAA is a life-threatening condition generally believed to be significantly under-diagnosed, and patients with TAA are at risk of death due to internal bleeding resulting from a ruptured aorta…